GLPG3970 is biologically inert in ulcerative colitis and rheumatoid arthritis, so Galapagos’s search for something better goes on.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.